[1]
|
Ferlay, J., Colombet, M., Soerjomataram, I., et al. (2019) Estimating the Global Cancer Incidence and Mortality in 2018: GLOBOCAN Sources and Methods. International Journal of Cancer, 144, 1941-1953. https://doi.org/10.1002/ijc.31937
|
[2]
|
Högner, A. and Moehler, M. (2022) Immunotherapy in Gastric Cancer. Current Oncology (Toronto, Ont.), 29, 1559-1574. https://doi.org/10.3390/curroncol29030131
|
[3]
|
Jin, X., Liu, Z., Yang, D., et al. (2022) Recent Progress and Future Perspectives of Immunotherapy in Advanced Gastric Cancer. Frontiers in Immunology, 13, Article ID: 948647. https://doi.org/10.3389/fimmu.2022.948647
|
[4]
|
Koizumi, W., et al. (2008) S-1 plus Cisplatin versus S-1 Alone for First-Line Treatment of Advanced Gastric Cancer (SPIRITS Trial): A Phase III Trial. The Lancet Oncology, 9, 215-221. https://doi.org/10.1016/S1470-2045(08)70035-4
|
[5]
|
Kawazoe, A., Fukuoka, S., Nakamura, Y., et al. (2020) Lenvatinib plus Pembrolizumab in Patients with Advanced Gastric Cancer in the First-Line or Second-Line Setting (EPOC1706): An Open-Label, Single-Arm, Phase 2 Trial. The Lancet Oncology, 21, 1057-1065. https://doi.org/10.1016/S1470-2045(20)30271-0
|
[6]
|
Xie, J., Fu, L. and Jin, L. (2021) Immunotherapy of Gastric Cancer: Past, Future Perspective and Challenges. Pathology, Research and Practice, 218, Article ID: 153322. https://doi.org/10.1016/j.prp.2020.153322
|
[7]
|
Postow, M.A., Callahan, M.K. and Wolchok, J.D. (2015) Immune Checkpoint Blockade in Cancer Therapy. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 33, 1974-1982. https://doi.org/10.1200/JCO.2014.59.4358
|
[8]
|
Kawazoe, A., Shitara, K., Boku, N., et al. (2021) Current Status of Immunotherapy for Advanced Gastric Cancer. Japanese Journal of Clinical Oncology, 51, 20-27. https://doi.org/10.1093/jjco/hyaa202
|
[9]
|
Robert, C., Thomas, L., Bondarenko, I., et al. (2011) Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. The New England Journal of Medicine, 364, 2517-2526. https://doi.org/10.1056/NEJMoa1104621
|
[10]
|
Kato, K., et al. (2019) A Subanalysis of Japanese Patients in a Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nivolumab for Patients with Advanced Gastric or Gastro-Esophageal Junction Cancer Refractory to, or Intolerant of, at Least Two Previous Chemotherapy Regimens (ONO-4538-12, ATTRACTION-2). Gastric Cancer: Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 22, 344-354.
|
[11]
|
Doi, T., et al. (2019) Phase 1 Trial of Avelumab (Anti-PD-L1) in Japanese Patients with Advanced Solid Tumors, Including Dose Expansion in Patients with Gastric or Gastroesophageal Junction Cancer: The JAVELIN Solid Tumor JPN Trial. Gastric Cancer: Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 22, 817-827. https://doi.org/10.1007/s10120-018-0903-1
|
[12]
|
Fuchs, C.S., Doi, T., Jang, R.W., et al. (2018) Safety and Efficacy of Pembrolizumab Monotherapy in Patients with Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncology, 4, E180013. https://doi.org/10.1001/jamaoncol.2018.0013
|
[13]
|
Shitara, K., et al. (2020) Efficacy and Safety of Pembrolizumab or Pembrolizumab plus Chemotherapy vs Chemotherapy Alone for Patients with First-Line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncology, 6, 1-10.
|
[14]
|
Doroshow, D.B., Bhalla, S., Beasley, M.B., et al. (2021) PD-L1 as a Biomarker of Response to Immune-Checkpoint Inhibitors. Nature Reviews. Clinical Oncology, 18, 345-362. https://doi.org/10.1038/s41571-021-00473-5
|
[15]
|
Bang, Y.J., Ruiz, E.Y., Van Cutsem, E., et al. (2018) Phase III, Randomised Trial of Avelumab versus Physician’s Choice of Chemotherapy as Third-Line Treatment of Patients with Advanced Gastric or Gastro-Oesophageal Junction Cancer: Primary Analysis of JAVELIN Gastric 300. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 29, 2052-2060. https://doi.org/10.1093/annonc/mdy264
|
[16]
|
Bang, Y.J., Cho, J.Y., Kim, Y.H., et al. (2017) Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 23, 5671-5678. https://doi.org/10.1158/1078-0432.CCR-17-0025
|
[17]
|
Kelly, R.J., Lee, J., Bang, Y.J., et al. (2020) Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 26, 846-854. https://doi.org/10.1158/1078-0432.CCR-19-2443
|
[18]
|
Pang, X., et al. (2023) Cadonilimab, a Tetravalent PD-1/CTLA-4 Bispecific Antibody with Trans-Binding and Enhanced Target Binding Avidity. MAbs, 15, Article ID: 2180794. https://doi.org/10.1080/19420862.2023.2180794
|
[19]
|
Zhang, L., Wang, Y., Li, Z., et al. (2021) Clinicopathological Features of Tumor Mutation Burden, Epstein-Barr Virus Infection, Microsatellite Instability and PD-L1 Status in Chinese Patients with Gastric Cancer. Diagnostic Pathology, 16, Article No. 38. https://doi.org/10.1186/s13000-021-01099-y
|
[20]
|
Gao, X., Mi, Y., Guo, N., et al. (2017) Cytokine-Induced Killer Cells as Pharmacological Tools for Cancer Immunotherapy. Frontiers in Immunology, 8, Article No. 774. https://doi.org/10.3389/fimmu.2017.00774
|
[21]
|
Moreno, V., Hernandez, T., De Miguel, M., et al. (2021) Adoptive Cell Therapy for Solid Tumors: Chimeric Antigen Receptor T Cells and Beyond. Current Opinion in Pharmacology, 59, 70-84. https://doi.org/10.1016/j.coph.2021.05.004
|
[22]
|
Shen, X., et al. (2007) Persistence of Tumor Infiltrating Lymphocytes in Adoptive Immunotherapy Correlates with Telomere Length. Journal of Immunotherapy (Hagerstown, Md.: 1997), 30, 123-129. https://doi.org/10.1097/01.cji.0000211321.07654.b8
|
[23]
|
Cao, B., Liu, M., Huang, J., et al. (2021) Development of Mesothelin-Specific CAR NK-92 Cells for the Treatment of Gastric Cancer. International Journal of Biological Sciences, 17, 3850-3861. https://doi.org/10.7150/ijbs.64630
|
[24]
|
Ishikawa, T., Okayama, T., Sakamoto, N., et al. (2018) Phase I Clinical Trial of Adoptive Transfer of Expanded Natural Killer Cells in Combination with IgG1 Antibody in Patients with Gastric or Colorectal Cancer. International Journal of Cancer, 142, 2599-2609. https://doi.org/10.1002/ijc.31285
|
[25]
|
Gabrilovich, D.I., Chen, H.L., Girgis, K.R., et al. (1996) Production of Vascular Endothelial Growth Factor by Human Tumors Inhibits the Functional Maturation of Dendritic Cells. Nature Medicine, 2, 1096-1103. https://doi.org/10.1038/nm1096-1096
|
[26]
|
Herbst, R.S., Arkenau, H.T., Santana-Davila, R., et al. (2019) Ramucirumab plus Pembrolizumab in Patients with Previously Treated Advanced Non-Small-Cell Lung Cancer, Gastro-Oesophageal Cancer, or Urothelial Carcinomas (JVDF): A Multicohort, Non-Randomised, Open-Label, Phase 1a/B Trial. The Lancet Oncology, 20, 1109-1123. https://doi.org/10.1016/S1470-2045(19)30458-9
|
[27]
|
Pardi, N., Hogan, M.J. and Weissman, D. (2020) Recent Advances in MRNA Vaccine Technology. Current Opinion in Immunology, 65, 14-20. https://doi.org/10.1016/j.coi.2020.01.008
|
[28]
|
Ajani, J.A., et al. (2006) An Open-Label, Multinational, Multicenter Study of G17DT Vaccination Combined with Cisplatin and 5-Fluorouracil in Patients with Untreated, Advanced Gastric or Gastroesophageal Cancer: The GC4 Study. Cancer, 106, 1908-1916. https://doi.org/10.1002/cncr.21814
|
[29]
|
Sato, Y., Shomura, H., Maeda, Y., et al. (2003) Immunological Evaluation of Peptide Vaccination for Patients with Gastric Cancer Based on Pre-Existing Cellular Response to Peptide. Cancer Science, 94, 802-808. https://doi.org/10.1111/j.1349-7006.2003.tb01522.x
|
[30]
|
Lv, J., Zhao, R., Wu, D., et al. (2019) Mesothelin Is a Target of Chimeric Antigen Receptor T Cells for Treating Gastric Cancer. Journal of Hematology & Oncology, 12, Article No. 18. https://doi.org/10.1186/s13045-019-0704-y
|
[31]
|
Caruso, H.G., Heimberger, A.B. and Cooper, L.J.N. (2019) Steering CAR T Cells to Distinguish Friend from Foe. Oncoimmunology, 8, E1271857. https://doi.org/10.1080/2162402X.2016.1271857
|
[32]
|
Bębnowska, D., Grywalska, E., Niedźwiedzka-Rystwej, P., et al. (2020) CAR-T Cell Therapy—An Overview of Targets in Gastric Cancer. Journal of Clinical Medicine, 9, Article No. 1894. https://doi.org/10.3390/jcm9061894
|